Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Medicine Co's Beginning Cash Position for the quarter that ended in Mar. 2026 was ¥3,167 Mil.
Zhejiang Medicine Co's quarterly Beginning Cash Position
increased
from Sep. 2025 (¥2,709 Mil) to Dec. 2025 (¥2,899 Mil) and
increased
from Dec. 2025 (¥2,899 Mil) to Mar. 2026 (¥3,167 Mil).
Zhejiang Medicine Co's annual Beginning Cash Position
increased
from Dec. 2023 (¥1,438 Mil) to Dec. 2024 (¥1,460 Mil) and
increased
from Dec. 2024 (¥1,460 Mil) to Dec. 2025 (¥1,966 Mil).
Zhejiang Medicine Co Beginning Cash Position Related Terms
Zhejiang Medicine Co Beginning Cash Position Historical Data
* Premium members only.
The historical data trend for Zhejiang Medicine Co's Beginning Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Medicine Co Beginning Cash Position Chart
What does a Beginning Cash Position of ¥3,167 Mil mean?
Zhejiang Medicine Co (SHSE:600216) has a Beginning Cash Position of ¥3,167 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Zhejiang Medicine Co and its competitors.
Is Zhejiang Medicine Co's Beginning Cash Position too high?
Zhejiang Medicine Co's current Beginning Cash Position is ¥3,167 Mil. Overall, Zhejiang Medicine Co has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Medicine Co's Beginning Cash Position compare to ZTS?
Zhejiang Medicine Co's Beginning Cash Position of ¥3,167 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Zhejiang Medicine Co and its competitors. Zhejiang Medicine Co's current Beginning Cash Position is ¥3,167 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Medicine Co (SHSE:600216) is currently considered Fairly Valued. The stock's GF Value™ is ¥13.72, compared to a current price of ¥12.42 — trading 9.5% below its estimated fair value. The current Beginning Cash Position is ¥3,167 Mil. Zhejiang Medicine Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Zhejiang Medicine Co (SHSE:600216), the current Beginning Cash Position is ¥3,167 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Medicine Co (SHSE:600216) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Medicine Co stock appears to be undervalued.
The current stock price of ¥12.42 is trading 9.5% below its estimated GF Value™ of ¥13.72.
GuruFocus considers Zhejiang Medicine Co to be Fairly Valued.
Key valuation signals for SHSE:600216:
Beginning Cash Position: ¥3,167 Mil
GF Value™: ¥13.72 vs. price of ¥12.42 (9.5% below fair value)
No single metric tells the full story. See the SHSE:600216 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Medicine Co Ltd is a china-based pharmaceutical company. The company manufactures fat-soluble vitamins, vitamins, quinolones, and antibiotic-resistant antibiotics, vitamin E, natural vitamin E, beta-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin.
70GF Score
Get the complete analysis for SHSE:600216
Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600216 has been successfully added to your 
